Spots Global Cancer Trial Database for Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma
Official Title: Phase II Trial to Evaluate the Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma
Study ID: NCT05135845
Study Description
Brief Summary: Immunotherapy with anti-PD1 antibodies provides encouraging results on a subset of patients. Capmatinib, a MET inhibitor, has shown an imunomodulatory effect and a synergy with spartalizumab a PD-1 inhibitor. The purpose of this phase II trial is to evaluate the efficacy and safety of the combination of capmatinib + spartalizumab in adult patients with advanced oesogastric adenocarcinoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hôpital Jean Minjoz, Besançon, , France
Centre François Leclerc, Dijon, , France
Centre Léon Bérard, Lyon, , France
AP-HP Hôpital Saint Louis, Paris, , France
Hôpital Haut Lévêque, Pessac, , France
Institut Universitaire du Cancer, Toulouse, , France
Institut Gustave Roussy, Villejuif, , France
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
